CN116813691B - 新的二肽类化合物及其用途 - Google Patents

新的二肽类化合物及其用途 Download PDF

Info

Publication number
CN116813691B
CN116813691B CN202310778549.2A CN202310778549A CN116813691B CN 116813691 B CN116813691 B CN 116813691B CN 202310778549 A CN202310778549 A CN 202310778549A CN 116813691 B CN116813691 B CN 116813691B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
pharmaceutical composition
compounds
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310778549.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN116813691A (zh
Inventor
李敏
黄雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Livzon Pharmaceutical Group Inc
Original Assignee
Livzon Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Livzon Pharmaceutical Group Inc filed Critical Livzon Pharmaceutical Group Inc
Priority to CN202310778549.2A priority Critical patent/CN116813691B/zh
Publication of CN116813691A publication Critical patent/CN116813691A/zh
Application granted granted Critical
Publication of CN116813691B publication Critical patent/CN116813691B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202310778549.2A 2018-10-29 2019-10-25 新的二肽类化合物及其用途 Active CN116813691B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310778549.2A CN116813691B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862751984P 2018-10-29 2018-10-29
US62/751,984 2018-10-29
CN201980082261.3A CN113195515B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途
PCT/US2019/057985 WO2020092139A1 (en) 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof
CN202310778549.2A CN116813691B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980082261.3A Division CN113195515B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途

Publications (2)

Publication Number Publication Date
CN116813691A CN116813691A (zh) 2023-09-29
CN116813691B true CN116813691B (zh) 2024-04-12

Family

ID=70464360

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310778549.2A Active CN116813691B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途
CN201980082261.3A Active CN113195515B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980082261.3A Active CN113195515B (zh) 2018-10-29 2019-10-25 新的二肽类化合物及其用途

Country Status (10)

Country Link
US (1) US12209141B2 (https=)
EP (1) EP3873916B8 (https=)
JP (1) JP7503561B2 (https=)
KR (1) KR102882178B1 (https=)
CN (2) CN116813691B (https=)
AU (1) AU2019371209B2 (https=)
CA (1) CA3117599A1 (https=)
IL (1) IL282676B1 (https=)
TW (1) TWI870362B (https=)
WO (1) WO2020092139A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117599A1 (en) * 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof
CN118496301A (zh) * 2023-02-16 2024-08-16 丽珠医药集团股份有限公司 一种二肽类化合物的盐、其制备方法和用途
WO2024169765A1 (zh) * 2023-02-16 2024-08-22 上海华汇拓医药科技有限公司 一种二肽类化合物的盐、其制备方法和用途

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017196A1 (en) * 1991-03-28 1992-10-15 Rhone-Poulenc Rorer International (Holdings) Inc. Anti-thrombotic peptides and pseudopeptides
EP1050534A1 (fr) * 1999-05-03 2000-11-08 Adir Et Compagnie Nouveaux dérivés de 2,3-methano-aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN1799596A (zh) * 2005-10-24 2006-07-12 丽珠医药集团股份有限公司 一种治疗脑中风的中药组合物及其制备方法
CL2008001724A1 (es) * 2007-06-13 2008-08-08 Bristol Myers Squibb Co Compuestos derivados de analogos dipeptidos, inhibidores del factor de coagulacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de un trastorno tromboembolico, infarto de miocardio, trombosis, ate
CN101460463A (zh) * 2006-03-29 2009-06-17 先灵公司 可作为凝血酶受体拮抗剂的单环和双环喜巴辛衍生物
CN102464701A (zh) * 2010-11-08 2012-05-23 上海医药工业研究院 一类新型化合物、其制备方法及用途
CN102796168A (zh) * 2011-05-27 2012-11-28 首都医科大学 一种具有溶血栓活性的化合物，及其制备方法和应用
CN103833827A (zh) * 2012-11-27 2014-06-04 上海医药工业研究院 一种酰胺类化合物、其药物组合物、制备方法及应用
CN105431418A (zh) * 2013-06-12 2016-03-23 维亚梅特制药公司 金属酶抑制剂化合物
CN106316975A (zh) * 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
CN113195515A (zh) * 2018-10-29 2021-07-30 华海美国公司 新的二肽类化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
JP4561696B2 (ja) * 1994-01-27 2010-10-13 三菱化学株式会社 プロリンアミド誘導体
US6774110B2 (en) * 2001-03-19 2004-08-10 Lg Life Sciences Ltd. Orally available peptidic thrombin inhibitors
FR2836143B1 (fr) * 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017196A1 (en) * 1991-03-28 1992-10-15 Rhone-Poulenc Rorer International (Holdings) Inc. Anti-thrombotic peptides and pseudopeptides
EP1050534A1 (fr) * 1999-05-03 2000-11-08 Adir Et Compagnie Nouveaux dérivés de 2,3-methano-aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN1799596A (zh) * 2005-10-24 2006-07-12 丽珠医药集团股份有限公司 一种治疗脑中风的中药组合物及其制备方法
CN101460463A (zh) * 2006-03-29 2009-06-17 先灵公司 可作为凝血酶受体拮抗剂的单环和双环喜巴辛衍生物
CN101784516A (zh) * 2007-06-13 2010-07-21 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
WO2008157162A1 (en) * 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
CL2008001724A1 (es) * 2007-06-13 2008-08-08 Bristol Myers Squibb Co Compuestos derivados de analogos dipeptidos, inhibidores del factor de coagulacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de un trastorno tromboembolico, infarto de miocardio, trombosis, ate
CN102464701A (zh) * 2010-11-08 2012-05-23 上海医药工业研究院 一类新型化合物、其制备方法及用途
CN102796168A (zh) * 2011-05-27 2012-11-28 首都医科大学 一种具有溶血栓活性的化合物，及其制备方法和应用
CN103833827A (zh) * 2012-11-27 2014-06-04 上海医药工业研究院 一种酰胺类化合物、其药物组合物、制备方法及应用
CN105431418A (zh) * 2013-06-12 2016-03-23 维亚梅特制药公司 金属酶抑制剂化合物
CN106316975A (zh) * 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
CN113195515A (zh) * 2018-10-29 2021-07-30 华海美国公司 新的二肽类化合物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A new oral anticoagulant: the 50-year challenge;David Gustafsson;《 nature reviews drug discovery 》;20040801;第103卷(第3期);第649-659页 *
L-脯氨酸-亮氨酸-甘氨酰胺治疗帕金森病的疗效观察;王增等;《上海医学》;19921231(第3期);第166-168页 *

Also Published As

Publication number Publication date
JP2022509366A (ja) 2022-01-20
KR102882178B1 (ko) 2025-11-05
IL282676A (en) 2021-06-30
US12209141B2 (en) 2025-01-28
JP7503561B2 (ja) 2024-06-20
CN113195515A (zh) 2021-07-30
EP3873916C0 (en) 2025-02-19
US20210395299A1 (en) 2021-12-23
CA3117599A1 (en) 2020-05-07
AU2019371209B2 (en) 2025-05-01
EP3873916A1 (en) 2021-09-08
EP3873916B8 (en) 2025-03-26
IL282676B1 (en) 2026-03-01
CN116813691A (zh) 2023-09-29
EP3873916A4 (en) 2022-08-10
AU2019371209A1 (en) 2021-05-27
KR20210086682A (ko) 2021-07-08
TW202031674A (zh) 2020-09-01
EP3873916B1 (en) 2025-02-19
TWI870362B (zh) 2025-01-21
CN113195515B (zh) 2024-11-15
WO2020092139A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
TWI359812B (en) Compounds, compositions and methods
CN113831301B (zh) 苯并噻唑类衍生物及其用途
CN116813691B (zh) 新的二肽类化合物及其用途
EP4079748A1 (en) Modulators of sortilin activity
EP2672821B9 (en) Cathepsin c inhibitors
JPWO2002074743A1 (ja) アリール置換脂環式化合物及びそれを含有する医薬組成物
JPH10175967A (ja) 新規なｎ−ベンジルピペラジン化合物、その製造法及びそれを含有する医薬組成物
CN108558760B (zh) 一类芳香酰胺化合物及其制备方法和用途
HK40094572B (zh) 新的二肽类化合物及其用途
HK40094572A (zh) 新的二肽类化合物及其用途
HK40060683A (en) Novel dipeptide compounds and uses thereof
HK40060683B (en) Novel dipeptide compounds and uses thereof
US20250179118A1 (en) Novel dipeptide compounds and uses thereof
CZ20011216A3 (cs) Benzamidové deriváty
KR20250036927A (ko) Irak3의 리간드 지정 분해제로서의 치환된 피라졸릴-피리디닐 화합물
CN119841819A (zh) 靶向bcr-abl的降解剂及其用途
HK40079290A (en) Benzothiazole derivative and application thereof
CN1984903A (zh) 1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐
JP2011073993A (ja) 抗凝固作用を有するキノキサリンカルボキサミド誘導体
NZ614540B2 (en) Cathepsin c inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094572

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant